pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CAR-T · news · pharmadog
← back to CAR-T
News · CAR-T
124
stories
Jun 6, 26
STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
stat
Jun 3, 26
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
biopharma dive
Jun 3, 26
STAT+: Legend Biotech emerged as a rare market winner
stat
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 2, 26
Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
endpoints
Jun 1, 26
#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
endpoints
May 28, 26
#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
endpoints
May 20, 26
STAT+: 23andMe offers to connect users’ DNA data with medical records
stat
May 15, 26
STAT+: A political contest in the U.K. could shake up drug pricing
stat
May 14, 26
Makary’s departure and Cassidy’s tenuous Senate seat
stat
May 14, 26
#ASGCT26 dispatch: In vivo CAR-T is everywhere
endpoints
May 14, 26
STAT+: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing
stat
May 14, 26
STAT+: The hunt for FDA’s next leader
stat
May 14, 26
Create Medicines raises $122M to bolster in vivo CAR-T therapies
biopharma dive
May 14, 26
Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data
endpoints
May 14, 26
STAT+: BeOne wins FDA approval in lymphoma race
stat
May 14, 26
STAT+: Why big digital health players are missing from Medicare’s chronic care experiment
stat
May 14, 26
STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study
stat
May 14, 26
STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
stat
May 14, 26
STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
stat
May 13, 26
Consensus Recommendations Address Key Controversies in Lymphoma Management
onclive
May 11, 26
Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
biopharma dive
May 7, 26
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
stat
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 7, 26
STAT+: Color me skeptical: Drinking gold is not an ALS cure
stat
May 6, 26
Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management
onclive
May 1, 26
J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
endpoints
Apr 30, 26
STAT+: Hair-raising trial results, and Servier’s M&A wishlist
stat
Apr 30, 26
STAT+: What does Akeso’s primo plenary spot say about its survival data?
stat
Apr 25, 26
Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
endpoints
← prev
page 4 of 5
next →
